The promise of anti-angiogenic cancer therapy.
Oehler
M K
MK
Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, UK.
Bicknell
R
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins; D002986:Clinical Trials as Topic; D003094:Collagen / Q000627:therapeutic use*; D043169:Endostatins; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D010958:Plasminogen / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen